Biogen (Denmark) A/SAktiv

CVR 21682977Stiftet 1999

Økonomiske nøgletal

178.728.185 kr.-23,6%
Omsætning 2025
-8,0%
Gennemsnitlig ændring pr. år 2017–2025
0100 mio.200 mio.300 mio.400 mio.’17’18’19’20’21’22’23’24’25

Nøgletal

2025
Balancens sammensætning
OmsætningsaktiverAnlægsaktiverGæld og hensatte forpligtelserEgenkapital
0100 mio.200 mio.300 mio.’17’18’19’20’21’22’23’24’25

Selskabsskat

indkomstår 2024
2024Skattepligtig indkomst 9.754.299 kr.2.145.924 kr.
2023Skattepligtig indkomst 10.478.743 kr.2.305.314 kr.
2022Skattepligtig indkomst 11.690.728 kr.2.571.954 kr.
2021Skattepligtig indkomst 10.593.976 kr.2.330.658 kr.
2020Skattepligtig indkomst 11.985.942 kr.2.636.898 kr.
2019Skattepligtig indkomst 36.825.957 kr.8.101.698 kr.
Selskabsskat →

Kilde: Skattestyrelsens offentlige skattelister for selskaber. Beregnet skat for indkomståret; kan være lavere end 22 % af indkomsten, fx ved skat betalt i udlandet. sktst.dk

Regnskabstal2017–2025
201720182019202020212022202320242025
Balance — aktiver
Likvide beholdninger56.240.81852.278.8949.086.643116.672.806114.037.75695.671.68586.319.560140.841.275134.887.887
Omsætningsaktiver i alt153.843.424197.824.470209.821.234176.218.147242.309.451158.978.906197.743.951190.374.743186.510.864
Anlægsaktiver i alt677.594796.669756.000989.307848.4901.365.219833.847736.823729.358
Aktiver i alt154.521.018198.621.139210.577.234177.207.454243.157.941160.344.125198.577.798191.111.566187.240.222
Balance — passiver
Kortfristede gældsforpligtelser74.245.084105.766.356104.652.68062.088.153120.645.35229.521.72959.265.47644.425.25934.997.811
Langfristede gældsforpligtelser743.000794.9381.579.587538.150375.182365.393431.935292.131264.082
Gældsforpligtelser i alt74.988.084106.561.294106.232.26762.626.303121.020.53429.887.12259.697.41144.717.39035.261.893
Selskabskapital501.000501.000501.000501.000501.000501.000501.000501.000501.000
Overført resultat79.031.93491.558.845103.843.967113.965.928121.517.771129.956.003138.294.742145.821.445151.385.117
Årets resultat9.095.75812.526.91112.285.12210.121.9617.551.8438.438.2328.338.7397.526.7035.563.672
Egenkapital i alt79.532.93492.059.845104.344.967114.466.928122.018.771130.457.003138.795.742146.322.445151.886.117
Resultatopgørelse
Omsætning349.466.112354.996.821324.931.439303.396.452259.684.984307.509.784259.564.233234.002.651178.728.185
Resultat af primær drift12.845.18817.374.21216.900.83514.498.80512.244.92611.642.8249.196.0418.423.2366.473.699
Resultat før skat11.950.44716.272.40215.954.68213.025.10610.498.01910.889.87910.729.9219.669.5377.230.276
Årets resultat9.095.75812.526.91112.285.12210.121.9617.551.8438.438.2328.338.7397.526.7035.563.672
Personaleomkostninger40.082.25834.158.78530.290.22530.505.87537.616.64434.778.49127.521.98123.919.01022.838.282
Af- og nedskrivninger—————————
Andre nøgletal
Ansatte272522242422201514

En streg (—) betyder, at der ikke er indsendt årsrapport, eller at posten ikke fremgår af den; 0 er et nul angivet i årsrapporten.

Om virksomheden

Årsrapport 2025

Biogen (Denmark) A/S is a company owned by Biogen Inc., which develops, manufactures and retailer drugs. Biogen (Denmark) A/S serves as the group’s Danish distributor of Avonex, Vumerity, Plegridy, Tysabri and Tecfidera within the MS segment in addition to rare asset portfolio and Biosimilar products.

The income statement for 2025 shows a profit of DKK 5,563,672 against a profit of DKK 7,526,703 last year, and the balance sheet at 31 December 2025 shows equity of DKK 151,886,117. The profit was a bit below expectations for 2025 given last year.Despite increased competition both on prices and products Biogen (Denmark) A/S has been able to maintain the profit. Biogen has globally succeeded in keeping its position in a growing market for treatment of multiple sclerosis during 2025 although rare diseases have further increased the investments. Results for the year are as expected.

Uddrag af ledelsesberetningen i den seneste årsrapport.

Biogen (Denmark) A/S — cvrprofil.dk